Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
I127961-100mg | 100mg | In stock | $79.90 | |
I127961-500mg | 500mg | In stock | $219.90 | |
I127961-1g | 1g | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $349.90 |
Synonyms | MFCD00866307 | AB00698464-10 | D08086 | (+)-7-ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate | (+)-Irinotecan | CPT-11 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | (+)-Irinotecan is an isomer of the Topo I inhibitor Irinotecan |
Storage Temp | Store at 2-8°C,Protected from light |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of DNA topoisomerase I |
Product Description | Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively. Irinotecan hydrochloride has been used: in combination with 5-fluorouracil for screening growth inhibitory functionality in MDA-MB-231 breast cancer cells. in chemosensitivity screening of high-grade appendiceal (HGA) and low-grade appendiceal (LGA) organoids. as a chemotherapeutic agent in the cytotoxicity studies in combination with heat shock proteins inhibitors (HPSC1) in HT29 colon cancer cells. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate |
---|---|
INCHI | InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1 |
InChi Key | UWKQSNNFCGGAFS-XIFFEERXSA-N |
Canonical SMILES | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7 |
Isomeric SMILES | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7 |
PubChem CID | 60838 |
Molecular Weight | 586.68 |
DrugBank Ligand | DB00762 |
---|---|
PubChem CID | 60838 |
CAS Registry No. | 97682-44-5 |
ChEMBL Ligand | CHEMBL481 |
Wikipedia | Irinotecan |
RCSB PDB Ligand | CP0 |
PEP | irinotecan |
DrugCentral Ligand | 1482 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2410409 | Certificate of Analysis | Jun 25, 2024 | I127961 |
G2410410 | Certificate of Analysis | Jun 25, 2024 | I127961 |
G2410411 | Certificate of Analysis | Jun 25, 2024 | I127961 |
G2222423 | Certificate of Analysis | May 21, 2024 | I127961 |
G2222454 | Certificate of Analysis | May 21, 2024 | I127961 |
I2104358 | Certificate of Analysis | Jun 13, 2023 | I127961 |
I2104359 | Certificate of Analysis | Jun 13, 2023 | I127961 |
G2222489 | Certificate of Analysis | Jun 11, 2022 | I127961 |
Solubility | Soluble in DMSO (10 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C). |
---|---|
Sensitivity | Light sensitive |
Pictogram(s) | GHS08, GHS05, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H315:Causes skin irritation H373:Causes damage to organs through prolonged or repeated exposure H302:Harmful if swallowed H318:Causes serious eye damage H361:Suspected of damaging fertility or the unborn child |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P270:Do not eat, drink or smoke when using this product. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P203:Obtain, read and follow all safety instructions before use. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P317:IF SWALLOWED: Get medical help. P305+P354+P338:IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. P318:if exposed or concerned, get medical advice. P317:Get emergency medical help. P332+P317:If skin irritation occurs: Get medical help. P319:Get medical help if you feel unwell. |
Starting at $12,825.90
Starting at $90.90
Starting at $813.90
Starting at $69.90
Starting at $32.90
Starting at $266.90
Starting at $697.90
Starting at $332.90
Starting at $41.90
Starting at $187.90
1. Yifan Wu, Xiaoxia Gong, Jianzhong Shen, Kui Zhu. (2023) Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages. Journal of Advanced Research, [PMID:37290606] [10.1016/j.jare.2023.05.010] |
2. Zhongcheng Yang, Zhijun Cao, Wenxin Wang, Ya Chen, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Luyong Zhang, Zheng Li. (2023) Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea. BIOORGANIC CHEMISTRY, 138 (106625). [PMID:37300962] [10.1016/j.bioorg.2023.106625] |
3. Lanhong Su, Wen Pan, Xiangxia Li, Xingyu Zhou, Xiaopeng Ma, Yuanzeng Min. (2023) Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. Acta Biomaterialia, 158 (698). [PMID:36563773] [10.1016/j.actbio.2022.12.039] |
4. Lanhong Su, Yuhao Hao, Rui Li, Wen Pan, Xiaopeng Ma, Jianping Weng, Yuanzeng Min. (2022) Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. Acta Biomaterialia, 154 (401). [PMID:36241013] [10.1016/j.actbio.2022.10.001] |
5. Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang, Fengguo Xu. (2022) Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”. Metabolites, 12 (6): (494). [PMID:35736427] [10.3390/metabo12060494] |
6. Jiao Yang Lu, Fu Rui Zhang, Xue Zhi Ding, Li Qiu Xia, Wei Tao Huang. (2022) Natural interface guiding cell: Directly using waste fish scales with rich micro/nano structures for control of cell behaviors. APPLIED SURFACE SCIENCE, 581 (152348). [PMID:] [10.1016/j.apsusc.2021.152348] |
7. Yue Shi-Jun, Qin Yi-Feng, Kang An, Tao Hui-Juan, Zhou Gui-Sheng, Chen Yan-Yan, Jiang Jian-Qin, Tang Yu-Ping, Duan Jin-Ao. (2021) Total Flavonoids of Glycyrrhiza uralensis Alleviates Irinotecan-Induced Colitis via Modification of Gut Microbiota and Fecal Metabolism. Frontiers in Immunology, 12 (1588). [PMID:34025639] [10.3389/fimmu.2021.628358] |
8. Dou-Dou XU, Xiao-Ying HOU, Ou WANG, Di WANG, Dan-Ting LI, Si-Yuan QIN, Bo LV, Xiao-Min DAI, Zun-Jian ZHANG, Jian-Bo WAN, Feng-Guo XU. (2021) A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan. Chinese Journal of Natural Medicines, 19 (364). [PMID:33941341] [10.1016/S1875-5364(21)60034-1] |
9. Ling Duan, Leijiao Deng, Dabin Wang, Shoucheng Ma, Chunmei Li, Da Zhao. (2017) Treatment mechanism of matrine in combination with irinotecan for colon cancer. Oncology Letters, 14 (2): (2300-2304). [PMID:28781667] [10.3892/ol.2017.6407] |
1. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin Jr AB, Stewart L. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog.. Proc Natl Acad Sci USA, 99 (24): (15387-92). [PMID:12426403] [10.1021/op500134e] |
2. Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, Antony S, Meng L, Liao Z, Kohlhagen G et al.. (2003) Repair of and checkpoint response to topoisomerase I-mediated DNA damage.. Mutat Res, 532 (1-2): (173-203). [PMID:14643436] [10.1021/op500134e] |
3. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR. (2004) Mechanisms of camptothecin resistance by human topoisomerase I mutations.. J Mol Biol, 339 (4): (773-84). [PMID:15165849] [10.1021/op500134e] |
4. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.. Cancer Chemother Pharmacol, 21 (1): (71-4). [PMID:3342468] [10.1021/op500134e] |
5. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T. (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.. Cancer Chemother Pharmacol, 21 (4): (308-12). [PMID:3370738] [10.1021/op500134e] |
6. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.. Cancer Res, 47 (22): (5944-7). [PMID:3664496] [10.1021/op500134e] |
7. Yifan Wu, Xiaoxia Gong, Jianzhong Shen, Kui Zhu. (2023) Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages. Journal of Advanced Research, [PMID:37290606] [10.1016/j.jare.2023.05.010] |
8. Zhongcheng Yang, Zhijun Cao, Wenxin Wang, Ya Chen, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Luyong Zhang, Zheng Li. (2023) Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea. BIOORGANIC CHEMISTRY, 138 (106625). [PMID:37300962] [10.1016/j.bioorg.2023.106625] |
9. Lanhong Su, Wen Pan, Xiangxia Li, Xingyu Zhou, Xiaopeng Ma, Yuanzeng Min. (2023) Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. Acta Biomaterialia, 158 (698). [PMID:36563773] [10.1016/j.actbio.2022.12.039] |
10. Lanhong Su, Yuhao Hao, Rui Li, Wen Pan, Xiaopeng Ma, Jianping Weng, Yuanzeng Min. (2022) Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. Acta Biomaterialia, 154 (401). [PMID:36241013] [10.1016/j.actbio.2022.10.001] |
11. Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang, Fengguo Xu. (2022) Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”. Metabolites, 12 (6): (494). [PMID:35736427] [10.3390/metabo12060494] |
12. Jiao Yang Lu, Fu Rui Zhang, Xue Zhi Ding, Li Qiu Xia, Wei Tao Huang. (2022) Natural interface guiding cell: Directly using waste fish scales with rich micro/nano structures for control of cell behaviors. APPLIED SURFACE SCIENCE, 581 (152348). [PMID:] [10.1016/j.apsusc.2021.152348] |
13. Yue Shi-Jun, Qin Yi-Feng, Kang An, Tao Hui-Juan, Zhou Gui-Sheng, Chen Yan-Yan, Jiang Jian-Qin, Tang Yu-Ping, Duan Jin-Ao. (2021) Total Flavonoids of Glycyrrhiza uralensis Alleviates Irinotecan-Induced Colitis via Modification of Gut Microbiota and Fecal Metabolism. Frontiers in Immunology, 12 (1588). [PMID:34025639] [10.3389/fimmu.2021.628358] |
14. Dou-Dou XU, Xiao-Ying HOU, Ou WANG, Di WANG, Dan-Ting LI, Si-Yuan QIN, Bo LV, Xiao-Min DAI, Zun-Jian ZHANG, Jian-Bo WAN, Feng-Guo XU. (2021) A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan. Chinese Journal of Natural Medicines, 19 (364). [PMID:33941341] [10.1016/S1875-5364(21)60034-1] |
15. Ling Duan, Leijiao Deng, Dabin Wang, Shoucheng Ma, Chunmei Li, Da Zhao. (2017) Treatment mechanism of matrine in combination with irinotecan for colon cancer. Oncology Letters, 14 (2): (2300-2304). [PMID:28781667] [10.3892/ol.2017.6407] |